2-[(2Z)-2-[(2Z)-2-[[3-(2-hydroxyethyl)-5-methoxy-1,3-benzothiazol-3-ium-2-yl]methylidene]butylidene]-5-methoxy-1,3-benzothiazol-3-yl]ethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-[(2Z)-2-[(2Z)-2-[[3-(2-hydroxyethyl)-5-methoxy-1,3-benzothiazol-3-ium-2-yl]methylidene]butylidene]-5-methoxy-1,3-benzothiazol-3-yl]ethanol
• 化学式: C25H29N2O4S2+
• 分子量: 485.6
• InChiKey: RRZNZHCNPLOAIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Use of thiazole inhibitors of fatty acid oxidation of formula (I) for the treatment of Alzheimer's disease and other neurological conditions
  申请人：Neuronautics, Inc.

  公开号：EP2090309A1

  公开（公告）日：2009-08-19

  Methods for inhibiting and/or reversing tau filament formation or polymerization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or polymerization. An especially preferred pharmaceutical composition contains an inhibitor of the general formula (I), wherein R1 is an aliphatic radical having one to six carbon atoms and wherein R2 and R3 independently are a second aliphatic radical having one to six carbon atoms, a hydroxyl-substituted aliphatic radical having one to six carbon atoms, or a pheny radical or a pharmaceutically acceptable salt of the inhibitor.

  本文提供了抑制和/或逆转tau丝形成或聚合的方法。这些方法通过施用抑制和/或逆转 tau 细丝形成或聚合的药物组合物，可用于治疗体内某些神经系统疾病。一种特别优选的药物组合物含有通式（I）的抑制剂，其中 R1 是具有 1 到 6 个碳原子的脂肪族基，R2 和 R3 分别是具有 1 到 6 个碳原子的第二个脂肪族基、具有 1 到 6 个碳原子的羟基取代的脂肪族基或苯基或该抑制剂的药学上可接受的盐。
• Methods for inhibiting or reversing tau filament fibrillization
  申请人：Kuret Jeff

  公开号：US20050032857A1

  公开（公告）日：2005-02-10

  Methods for inhibiting and/or reversing tau filament formation or fibrillization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or fibrillization. A preferred composition comprises 3-(2-hydroxyethyl)-2-[2-[[3-(2-hydroxyethyl)-5-methoxy-2-benzothiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium.

  本文提供了抑制和/或逆转tau丝形成或纤维化的方法。通过施用抑制和/或逆转tau丝形成或纤维化的药物组合物，这些方法可用于治疗体内某些神经系统疾病。一种优选的组合物包含3-(2-羟乙基)-2-[2-[[3-(2-羟乙基)-5-甲氧基-2-苯并噻唑亚基]甲基]-1-丁烯基]-5-甲氧基苯并噻唑鎓。
• EP1418910A4
  申请人：——

  公开号：EP1418910A4

  公开（公告）日：2005-01-05
• METHODS FOR INHIBITING OR REVERSING TAU FILAMENT FORMATION POLYMERIZATION
  申请人：Neuronautics, Inc.

  公开号：EP1418910A1

  公开（公告）日：2004-05-19
• METHODS FOR INHIBITING OR REVERSING TAU FILAMENT FIBRILLIZATION
  申请人：Neuronautics, Inc.

  公开号：EP1643994A2

  公开（公告）日：2006-04-12